Testing for oncogenic activation of tyrosine kinases, such as those mediated by EGFR mutations and ALK rearrangements, has become standard practice during diagnostic evaluation of NSCLC adenocarcinoma patients and has led to wide adoption of targeted therapies and greatly improved outcomes for patients with these types of genetic modifications [35]. The gene discussed is ALK; the disease is adenocarcinoma.